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Abstract
Background: Many HIV patients receiving antiretroviral treatment develop lipodystrophy. NEW-FILLW is a polylactic
acid injected to treat facial lipoatrophy. The objectives of this study were to describe (1) change in quality of life
(QoL) of HIV patients treated with NEW-FILLW in the management of facial lipoatrophy; (2) efficacy of NEW-FILLW
using facial photographs and (3) a patient-reported “Overall Treatment Effect” (OTE) scale; and (4) safety of NEW-
FILLW.
Methods: Doctors from 13 treatment centres recruited 230 HIV patients to receive up to 5 sessions of NEW-FILLW
injections. Patients self-reported QoL with the ABCD questionnaire before the first set of injections, at 2 months and
at 12 to 18 months after the last session of injections. Efficacy was evaluated at each interval through photographs
and OTE scale. Safety was evaluated via Case Report Form (CRF) data.
Results: 64.4% of patients reported QoL improvements of >10% at 2 months, and 58.8% at 12–18 months.
Lipoatrophy grades improved at each visit (“no lipoatrophy” or “limited lipoatrophy”: 20.3% at inclusion, 77.4% at 2
months, 58.4% at 12–18 months). Average OTE scores of 5.3 and 5.0 at 2 and 12–18 months indicated “moderate
improvement”. Minimum Important Difference (MID) in QoL score was 7.1 points at 2 months; 7.4 points at 12–18
months. For 911 injection sessions performed, 3.4% resulted in “immediate” adverse events, 7% in “non-immediate”
events, and 1.7% in “other” events.
Conclusions: Improvements to quality of life and diminished lipoatrophy visibility were observed in the months
immediately following NEW-FILLW treatment and were maintained 12–18 months post-treatment. Most adverse
events were mild and transient. ABCD MID thresholds provide clinicians with means to assess the impact of
lipoatrophy therapies on QoL.
Background
The use of antiretroviral agents for treatment of HIV infec-
tion has made it possible to considerably improve morbid-
ity and mortality associated with HIV infection. But their
use exposes patients to adverse events in the medium and
long term. Lipodystrophy syndrome is one of the main
effects in the long term observed in patients treated with
antiretroviral agents. Lipodystrophy is probably the result
of the synergistic effect of several classes of medicinal
products because some protease inhibitors (PI) inhibit adi-
posity differentiation and induce insulin resistance while
some nucleoside inhibitors (NI) produce lipolysis and,
under some conditions, apoptosis of adipocytes. The differ-
ence in sensitivity of peripheral and central adipocytes to
these compounds may partly explain the redistribution of
fat, keeping in mind that other mechanisms are probably
involved [1].
Many cross-sectional studies have demonstrated the
prevalence of lipodystrophy ranging from 18 to 80% in
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patients who received antiretroviral therapy [2-5]. It is
estimated that about 50% of patients develop lipodystrophy
after one to two years of exposure to multiple drug therapy
including a protease inhibiter (PI) [6].
The psychological impact of lipodystrophy is substan-
tive [7,8]. Physical changes, especially facial atrophy,
stigmatise patients and affect compliance with therapy
[9] and patient’s quality of life [8,10]. The success of
antiretroviral therapy to a large extent is based on pa-
tient compliance with therapy [11]. The Aproco [9] co-
hort clearly demonstrated the relationship between
lipodystrophy and non-compliance with therapy. It is
therefore important to improve the impact of therapies
on quality of life and consequently on compliance.
One method of managing facial lipoatrophy is to inject
filler products. Two main types can be differentiated,
permanent filler products and absorbable filler products.
NEW-FILLW or L-Polylactic Acid is an absorbable filler
product whose purpose is to produce progressive thick-
ening of the dermis by deep intradermal injection. Its slow
absorbability gives it an extended duration of action [12].
In France, L-polylactic acid (NEW-FILLW) is a medical
device which obtained a favourable opinion from the
Commission for Evaluation of Products and Services
(CEPP) [13] for reimbursement in correction of facial
lipoatrophy in HIV-positive patients treated with anti-
retroviral therapies. The impact of this treatment on
patients’ quality of life has not previously been addressed.
The objectives of this study were four-fold: [1]. The
primary objective was to describe the impact of NEW-
FILLW on the quality of life of patients treated with anti-
retroviral agents, using the lipodystrophy-specific ABCD
quality of life self-questionnaire [14,15]. The secondary
objectives of this study were: [2] to describe the efficacy
of NEW-FILLW based on photographs taken before the
first injection, 2 months after the last injection session,
and then, if applicable, 12 and 18 months after the last
injection session; [3] to describe overall efficacy of treat-
ment with an “Overall Treatment Effect” (OTE) scale
[16]; [4] to contribute further data regarding the safety
of NEW-FILLW in the short, medium and long term.
Method
Design
This was an observational, longitudinal, multicenter,
open label study performed in France. The study fol-
lowed patients during their usual care routine. Add-
itional information pertaining to the study was asked for
during usual care visits. It did not alter patients’ usual
medical management nor affect their physical or psycho-
logical integrity nor require specific monitoring visits. A
participation consent form was signed jointly by patient
and investigating doctor. The study was approved by the
Paris Ile de France 4 Ethics Committee, Paris, France.
The study was conducted in compliance with the Helsinki
Declaration [17], with the French Data Processing and
Liberties Law no 78.17 of 06.01.1978, received a favourable
opinion from the CCTIRS (Consultative Committee on
Data Processing in Research in the field of Health), and
was authorised by CNIL (National Commission on Data
Processing and Liberties).
Schedule
The first patient was included in April 2006 and the last
in April 2007. Final follow-up with the last patient oc-
curred in February 2009.
Recruitment of doctors and patients
Thirteen ‘investigating’ doctors were recruited from 13
centres where NEW-FILLW treatment was provided. In-
vestigating doctors were recruited from a list of all
doctors trained in the injection technique who had
treated at least one patient with NEW-FILLW. A total of
200 patients were recruited from the 13 centres and
comprised the first 20 patients from each centre agree-
ing to participate in the study and who met eligibility
criteria during a 6 month period.
Inclusion/non-inclusion criteria
Inclusion criteria were: men or women at least 18 years
of age, HIV-seropositive, treated with antiretroviral ther-
apy and for whom the doctor freely decided to use
NEW-FILLW to correct facial lipoatrophy, who agreed to
participate in the study and who signed the consent
form, with an adequate level of education to be able to
fill out alone the self-questionnaires on evaluation of
quality of life and overall efficacy of treatment. Non-
inclusion criteria were: patients participating in another
study with a similar product.
Data collection
Patients completed the ABCD quality of life question-
naire before the first injection and then 2 months after
the last session of injections and, if applicable, 12 to 18
months after the last session of injections. Concomi-
tantly, the Overall Treatment Effect (OTE) scale was
completed by patients 2 months after the last session of
injections and 12 to 18 months after the last session of
injections, if applicable*. Comparison of ABCD and
OTE scores allowed calculation of the minimal import-
ant difference in overall ABCD quality of life score.
*As it was an observational study the 12/18 months
evaluation took place only if the patient returned to a visit
during this period in the setting of usual management
An expert committee (2 dermatologists, 1 plastic sur-
geon) graded photographs for lipoatrophy presence before
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the 1st injection, 2 months after the last session of injections
and, if applicable, 12 to 18 months after the last session of
injections. Safety was evaluated using side effect or adverse
event data obtained from the Case Report Forms (CRF).
The Assessment of Body Change and Distress (ABCD)
questionnaire [14] consist of three parts. Lipodystrophy:
Six items concern the presence/absence of lipodystrophy
in 6 areas of the body. The score is calculated by adding
up the total number of responses (0 or 1) to the 6 items
(0= no area affected 6 = 6 areas affected). Satisfaction:
One 5-point item investigates overall satisfaction with
body appearance (from 1 = very dissatisfied to 5 = very
satisfied). Quality of life: 21 items spread across four
dimensions evaluate the impact of lipodystrophy on the
patient’s life; Dimension A: Control and adjustment to
the illness, satisfaction with body appearance (9 items);
Dimension B: Psychological, social and relational impact
(7 items); Dimension C: Fear of the future (3 items);
Dimension D: Impact of treatment (2 items). Note that
this French ABCD questionnaire contains an additional
item concerning surgery/aesthetic correction of lipo-
dystrophy in Dimension B. Quality of life items were
summed to form an overall QoL score (Cronbach’s
alpha 0.89), t-transformed to range from 0 = worst pos-
sible QoL to 100 = best possible QoL.
Lipoatrophy grading system [18]. For each patient,
photographic slides (each containing 3 views: 1 front, 1
right side, 1 left side) were submitted to a committee of 3
experts in random order, blinded (before treatment/after
treatment or after treatment/before treatment), and with-
out indication of the injection site. The experts rated the
presence of lipoatrophy in each photo according to a grad-
ing system which differentiates 4 stages of lipoatrophy:
Grade 1: corresponds to limited lipoatrophy, localised to
the face. The appearance is almost normal. Grade 2:
corresponds to deeper lipoatrophy. Some muscles begin
to be visible, in particular the zygomatic. Grade 3: the
affected area is no longer localised solely to the cheeks but
is also deeper and wider. The muscles are increasingly vis-
ible. Grade 4: the most serious condition, also shows dam-
age to the orbits. In this study, Grade 0 (no lipoatrophy)
was added to the grading system. Photographs of patients
were classified into one of 5 stages before treatment and
then again classified at the visit at 2 months after treat-
ment and at 12–18 months after treatment.
The Overall Treatment Effect (OTE) scale [16] is a global
rating of change scale. It comprises a single item on which
patients rate the overall effect of treatment on their condi-
tion on a 15-point scale, where −7 = condition greatly
worsened, 0 = no change, +7 = condition greatly improved.
Adverse events likely to be associated with injection of
NEW-FILLW were classified as follows: “immediate” ad-
verse events, such as bleeding, redness at the injection site,
pain, ecchymosis and facial oedema. These coincided to
time of injection. “Non-immediate” adverse events, such
as nodules and/or indurated areas, granulomas, inflamma-
tion, discolouration, allergic reactions, coetaneous hyper-
trophy and atrophy. Clinically, they were of late onset.
They are difficult to attribute to a particular session of
injections because they can result from successive effect of
several sessions of injections. When an adverse event was
not an expected event (in conformity with the product
leaflet), it was classified as “other” and entered according
to the doctors verbatim.
Statistical methods
Statistical analyses were performed with SAS software,
version 8.2 [19]. Data were described in terms of sample
size, mean, standard error, percentage by modality, re-
sponse, and number of missing data, pre- (time 1) and
post-treatment (time 2: 2 months; time 3: 12–18 months).
Evaluation of quality of life was performed based on a
score calculated according to recommendations of the
ABCD questionnaire. Wilcoxon t-tests were used to deter-
mine the significance of within-group changes over time
in QoL component scores between the inclusion or pre-
treatment visit (time 1) and post-treatment visits (time 2,
time 3). Determination of the minimal important differ-
ence in quality of life was derived from calculation of the
pre-treatment (time 1) and post-treatment (time 2, time 3)
change in QoL score that corresponded with an OTE rat-
ing [2,3] of a condition ‘a little improved’ or ‘somewhat
improved’. Evaluation of photographs pre- (time 1) and
post-treatment (times 2,3) were performed by a com-
mittee of experts according to the scale for classification
of lipoatrophy. Frequency of reported side effects were
calculated.
Results
Participant data collected from 230 patients between April
2006 and February 2009 were analysed. Patient charac-
teristics are shown in Table 1. Patients were 47.4 years of
age on average. Eighty-seven percent of participants were
male. The average duration of HIV infection was around
16 years and time since initiation of anti-retroviral therapy
was 11.2 years. Time since diagnosis of facial lipoatrophy
was 5 years. Previous treatment of facial lipoatrophy was
found in 39.4% of patients (NEW-FILLW in 75% of cases).
CD4 count was greater than or equal to 350 CD4/mm3 in
74.5% of patients; almost 85% of patients had a viral load
of less than 400 copies/ml and almost 60% had a viral load
of less than 50 copies/ml. The most frequently observed
combinations of antiretroviral agents were 2 Nucleosid
Reverse-Transcriptase Inhibitors (NRTI) + 1 Protease In-
hibitor (PI) (36.1%) and 2 NRTIs +1 non-NNRTI (Non-
Nucleoside Inhibitor; 21.3%). Demographic characteristics
of patients evaluated at 12–18 months and of patients lost
to follow-up were very similar (Mean age: 48.2 years vs.
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46,7 years respectively, % men: 84.9% vs. 88.7% respectively,
mean body mass index (BMI): 21.4 kg/m2 vs. 21.7 kg/m2
respectively).
Data on 911 sessions of injections were collected on the
230 patients, i.e. a mean of 4 sessions of injections per pa-
tient. Over half of the patients (51.3%) had 5 sessions of
injections of NEW-FILLW.
Injection sessions most often involved the cheeks
(98.9%) and temples (37.7%). Other facial areas were a
rarer focus (7.7%). One hundred and ninety-seven
patients had an evaluable ABCD questionnaire at inclu-
sion (at least 50% of items completed), an evaluable
ABCD questionnaire at one monitoring visit and an
OTE questionnaire filled out at the same monitoring
visit. One hundred and seventy-seven patients had a
photograph considered evaluable at inclusion and at the
monitoring visit at 2 months. A photograph was
considered evaluable if it could be classified by the ex-
pert committee according to the lipoatrophy grading
system. Patients for whom the course of NEW-FILLW
was not followed by a monitoring visit at 12–18 months
after the last injection session or whose evaluation visit
at 12–18 months was not evaluable were considered as
lost to follow-up. Of the 230 patients included, 124 were
lost to follow-up.
The first and primary objective of this study was to de-
scribe the change in quality of life of patients treated
with NEW-FILLW in the setting of management of facial
lipoatrophy in HIV-seropositive subjects treated with
antiretroviral agents. Results of the study showed signifi-
cant improvement in all mean scores on the ABCD
questionnaire measured between inclusion and moni-
toring visits at 2 months and 12 to 18 months (see
Table 2). Between the inclusion visit and 2 month visit,
64.4% of patients had an improvement in their overall
quality of life score (QoL) of at least 10% and in ad-
dition, 27,8% of patients had an improvement in their
QoL score of at least 50%. Between inclusion visit and
12–18 month visit, 58.8% of patients improved their
overall quality of life score by at least 10%, and 22.7%
had an improvement of at least 50%.
Overall quality of life scores of patients evaluated at
12–18 months and of patients lost to follow-up were
similar at inclusion (57.2 vs. 55.9 respectively) and at the
monitoring visit at 2 months (70.0 vs. 69.9 respectively).
Lipodystrophy scores of patients evaluated at 12–18
months and patients lost to follow-up were similar at
the inclusion visit on average (mean score of 3.3 in the 2
sub-groups). At the monitoring visit at 2 months, the
lipodystrophy score of patients evaluated at 12–18
months appeared as slightly higher than that of patients
lost to follow-up on average (mean scores of 2.3 and 2.1
respectively). Patients lost to follow-up after the visit at
2 months, therefore, were not patients who said that
their condition worsened. The satisfaction score at the
inclusion visit for patients lost to follow-up was slightly
higher than that of patients evaluated at 12–18 months
on average (2.7 vs. 2.5 respectively). At monitoring visit
at 2 months, the satisfaction scores of patients evaluated
at 12–18 months and patients lost to follow-up were si-
milar on average (3.3 for the 2 sub-groups). The patients
lost to follow-up after the visit at 2 months therefore
were not dissatisfied patients.
The second objective of the study was to describe effi-
cacy of NEW-FILLW based on photographs taken before
the first injection, 2 months after the last session if
injections, and then, if applicable, 12 to 18 months after
the last session of injections.
Analysis of photographs taken at the inclusion visit
and at monitoring visits of 2 months and 12–18 months
was performed according to the lipoatrophy grading sys-
tem (see Table 3). The results of the study demonstrated
a significant improvement in grade of lipoatrophy be-
tween the inclusion visit and monitoring visit (Grades 0
or 1: 20.3% at inclusion, 77.4% at 2 months, 58.4% at the
12–18 months). Furthermore, 55.4% of patients saw
their lipoatrophy decrease by one grade between inclu-
sion visit and the monitoring visit at 2 months, 31.6% by
two grades. Similarly, 46.7% of patients saw their lipo-
atrophy decrease by one grade between the inclusion
visit and the monitoring visit at 12–18 months, 23.3% of
patients by two grades.
Table 1 Patient characteristics
Total population Quality of life population Photographed population
N=230 N=197 N=177
Age (years) 47.42 (8.40) 47.85 (8.47) 48.09 (8.78)
Sex (Male) 87.0% 86.8% 87.6%
Body Mass Index 21.59 (2.56) 21.62 (2.50) 21.63 (2.45)
Duration of HIV seropositivity (years) 16.00 (4.37) 16.10 (4.29) 16.11 (4.35)
CD4 count (CD4/mm3) 543 (299) 547 (288) 551 (306)
Viral load (< 400 copies/ml) 84.9% 84.7% 84.0%
Time since antiretroviral therapy initiated (years) 11.55 (4.02) 11.69 (3.90) 11.74 (3.98)
Note: Means are provided for continuous variables with standard error of measurement (SEM) in parentheses.
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The third objective of the study was to describe over-
all efficacy of treatment with the OTE questionnaire
(scored −1 to −7 in the case of a worsened condition, 0
in case of no change and +1 to +7 in the case of improve-
ment). The average OTE questionnaire scores at moni-
toring visits 2 months and 12–18 months were 5.3 ± 1.5
and 5.0 ± 1.9 respectively (with ‘5’ indicating a moderate
improvement in condition due to treatment). No patient
mentioned deterioration. The minimum reported score was
0 (“no change”).
Table 4 shows changes in ABCD QoL scores between
inclusion and monitoring visits that correspond with clin-
ically important difference thresholds. OTE data indicated
that the minimal clinically important change in the overall
ABCD QoL score was 7.1 points between inclusion and
monitoring visit at 2 months and 7.4 points for the
monitoring visit at 12–18 months. Improvements of this
magnitude in QoL scores corresponded with OTE ratings
of 2 or 3 points reflecting a condition ‘a little better’ or
‘somewhat better’. A moderate important change (4 or 5
point OTE rating) for the QoL score was 11.1 for the
monitoring visit at 2 months and 5.9 for monitoring visit
at 12–18 months. The maximal important change (6 or 7
point OTE rating) for the quality of life score was 16.1 on
average for the monitoring visit of 2 months and 14.2 for
monitoring visit at 12–18 months.
The fourth objective of the study was to describe
safety of NEW-FILLW in the short, medium, and long-
term. The occurrence of at least one adverse event
whatever the type was reported for 34 patients (14.8%).
19 patients (8.3%) had at least one “immediate” adverse
event. Out of 911 injection sessions performed, at least
1 “immediate” adverse event was reported for 31 injec-
tion sessions (3.4%). Among these “immediate” adverse
events, ecchymosis (1.9% of injection sessions), pain (1%
of injection sessions) and redness at the injection site
(0.5% of injection sessions) were the most common
effects.
At least one “non-immediate” adverse event was
reported by 16 patients (7%). The most frequently
reported “non-immediate” adverse events were nodules
and/or indurated areas (3.9% of patients); the occurrence
of granulomas was reported in 2 patients (0.9%). Median
times of occurrence of these adverse events after start of
the course of therapy were 75 days for nodules and/or
indurated areas and 40 days for granulomas. In agreement
with legislation on medical device vigilance, as a result
of administration of corrective therapy, one of the cases
of granuloma was reported as a “serious” adverse event.
Granulomas regressed in 2 cases of occurrence. Regres-
sion of nodules and/or indurated areas, inflammation and
coetaneous hypertrophy was reported in 33.3%, 66.7% and
50.0% of cases respectively. Four patients (1.7%) were the
subject of reporting of an “other” adverse event. In all
cases, it involved malaise which occurred on the day of
injection.
Table 3 Facial lipoatrophy (FL) grades based on













1 19.2% 42.9% 37.1%
2 48.0% 16.9% 30.3%
3 27.1% 5.6% 11.2%
4 4.5% 0.0% 0.0%
Grades range from 0 (no FL), 1 (Slight localised facial lipoatrophy), 2 (Longer
and deeper atrophy with start of appearance of facial muscles), 3 (Deeper and
wider area of atrophy, facial muscles clearly apparent), 4 (Lipoatrophy covering
a wide area, with extension to the eye orbits and facial skin resting directly on
the muscles).








Lipodystrophy score 3.31 (1.14) 2.23 (1.72)* 2.14 (1.61)*
Overall satisfaction with body image 2.56 (0.91) 3.30 (1.03)* 3.13 (1.01)*
Dimension A: Control and adjustment to illness, satisfaction with body
image
53.13 (21.24) 67.84 (23.73)* 66.19 (20.04)*
Dimension B: Psychological, social and relational impact 52.13 (22.85) 67.37 (22.84)* 65.08 (18.62)*
Dimension C: Fear of the future 60.00 (24.04) 70.53 (24.08)* 65.08 (18.62) †
Dimension D: Impact of treatment 83.74 (21.09) 87.63 (19.74)* 86.60 (19.87) †
Overall ABCD quality of life score 56.55 (18.97) 69.93 (20.53)* 67.92 (16.91)*
* Comparison with score at inclusion: Wilcoxon Test, p = <0.001.
† Comparison with score at inclusion: Wilcoxon Test, p = <0.05.
Means provided with standard error of measurement (SEM) in parentheses.
Scores for Dimensions A to D are t-transformed where 0 = worst and 100 = best possible QoL.
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Discussion
This study investigated [1] changes in patient perceptions
of quality of life following lipoatrophy treatment with
NEW-FILLW, [2] the efficacy of NEW-FILLW based on
photographs taken before and after treatment [3], patients
perception of overall treatment effect, and [4] safety of
NEW-FILLW in terms of adverse treatment-related events.
Patients reported significant improvements in all aspects
of quality of life following treatment. Concerns about HIV
treatment reduced, as did fears for the future. Psycho-
logical, social and relational aspects of quality of life were
especially improved, as was satisfaction with body appear-
ance. Heightened scores on the latter QoL dimensions de-
monstrate the value of having used a condition-specific
QoL instrument to assess the impact of condition-targeted
treatment. These dimensions, encompassing intrapersonal
and interpersonal stigma and appearance, are most indica-
tive of lipoatrophy QoL effects [12] while HIV treatment
concerns and future fears relate to HIV QoL more gener-
ally [10,20,21]. Similar studies using generic QoL measures
such as the SF-36 have sometimes failed to find significant
treatment gains [22], while others have failed to show QoL
differences between patients with and without lipodystro-
phy [4]. On the other hand, studies using the ABCD have
reported comparable results [23,24].
Patient-reported QoL improvements corresponded with
doctor ratings of lipoatrophy reductions in facial disfigure-
ment and musculature visibility observed in patient photos
at three time intervals. Approximately half of patients saw
their lipoatrophy decrease by at least one grade, and a
quarter decreased by two grades between visits at 2
months and 12–18 months. Previous studies of the impact
of absorbable injection therapies [e.g. polyactic acid (PLA)]
have also shown convergence between patient-reported
QoL improvements and clinician-reported improvements
in lipoatrophy [25]. This convergence of views differs from
some studies in which surgery has been the treatment of
choice, and in which clinicians reported surgical success
while patients reported significant QoL issues arising from
post-surgery complications. Moreover, comparative studies
have shown greater patient-reported QoL gains resulting
from reabsorbable (PLA) and non-reabsorbable [e.g. poly-
acrylamide hydrogel (PAAG)] filler injections when
compared to autologous fat transfer (AFT) surgery
[23]. This speaks to the value of including both patient
and doctor perspectives as a method of evaluating con-
dition improvement, and to the use of filler injection
techniques as the treatment of choice.
Patient ratings of the overall treatment effect were posi-
tive in all cases, with most declaring a moderate improve-
ment. No patient mentioned deterioration in condition
as a result of treatment. A within subject change of 2–3
points in overall treatment effect (‘a little improved’ or
‘somewhat improved’) equated with approximately 7 points
change in ABCD quality of life score, indicating the min-
imal clinically important difference threshold for the
ABCD QoL scale. Thresholds were determined for changes
in ABCD QoL score for short and longer-term follow-up
assessment (2 and 18 months), and for determining moder-
ate and major important differences. With this knowledge,
treating health professionals can easily and effectively moni-
tor the magnitude of impact of a lipoatrophy treatment
without the interpretive ambiguity typically associated with
other QoL instruments. Furthermore, clinicians need not
rely upon expensive and complicated diagnostic procedures
and equipment to assess the need for patient intervention.
In this study, the primary criterion to assess the im-
pact of lipoatrophy was the subjective perception of
patients. It can be seen that this criterion is extremely
useful in the clinical assessment of need for lipoatrophy
correction, and may be a better indicator of treatment
need than medical assessment procedures commonly
used in clinical trials such as DEXA scan, bioimpedance
or sonography. For instance low sensitivity poses a prob-
lem for the use of sonography to detect LD in the clin-
ical routine as a single exam [24].
Treatment safety data concur with the findings of previ-
ous studies [26-29]. Immediate adverse events were re-
ported by around 8% of patients, with ecchymosis, pain and
skin redness being the most common. Non-immediate
events affected around 7% of patients, with nodules and
inflammation being the most frequently reported. These
essentially mild and transient events, coupled with sig-
nificant QoL gains and visible lipoatrophy improve-
ments, speak to the value of preferencing cosmetic filler
therapy over surgery for which there are greater imme-
diate risks such as disfigurement, expertise required,
lack of long-term safety data, and limits to whom sur-
gery is applicable [22].
In terms of clinical value, compliance with anti-
retroviral therapy may well improve with the use of
NEW-FILLW. The success of ART is largely based on pa-
tient compliance with therapy [11], and lipodystrophy
diminishes compliance [9]. As shown here, improvements
to lipoatrophy occurred following NEW-FILLW treatment
Table 4 Minimal, moderate and maximal important
































7.11 7.38 11.10 5.89 16.08 14.18
(9.74) (12.88) (18.00) (13.80) (18.56) (15.51)
Note: Means provided with SEM in parentheses.
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in ways that were meaningful and recognisable to both
doctor and patient.
Limitations
One limitation is the observational design of the study. Im-
provement in QoL may not solely be attributed to treat-
ment. However, spontaneous improvement of lipoatrophy
does not occur. Consistent patient improvements observed
in the photographs add weight to the validity of the results.
Moreover, the efficacy of polyactic acid when compared to
other treatments has been shown in several previous com-
parative studies [22,23,27-29]. A second limitation is the
loss of patients to followup, though data available indicated
that those lost had similar demographics and treatment
outcomes in the early stages to those retained in the later
stage. Thirdly, most participants were male hence the
findings best represent the treatment experience of men
rather than women. A fourth limitation is the use of a
single-item measure to establish MID. The reliability of a
single item global measure of change is low, and it is
strongly influenced by the present state and only weekly by
the initial state. Others studies have used multiple item
measures, effect size, and combined clinical-patient ratings
of overall treatment effect for MID calculation.
Conclusions
In summary, the results demonstrated an improvement
in quality of life scores as well as a favourable change in
visual grade of lipoatrophy between inclusion visit and
monitoring visit at 2 months post-NEW-FILLW treat-
ment. These improvements were maintained 12–18
months after the end of the course of therapy. The ma-
jority of adverse events reported were mild and transi-
ent. The occurrence of nodules or granulomas remained
infrequent.
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